Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05553197

Intersession Processes in Psychotherapeutic Treatments Using an Ecological Momentary Assessment Approach (ISA-Bell)

The effects of a monitoring intervention as an add-on to face-to-face Cognitive Behavioral Therapy (CBT) for depression are assessed in this randomised trial. Monitoring consists of Ecological Momentary Assessment (EMA) of symptoms and inter-session processes via mobile phones. Twenty sessions of face-to-face CBT + EMA are compared to twenty sessions of face-to-face CBT (treatment as usual, TAU). 84 patients with mild to moderate depression will be randomised to CBT + EMA or to TAU.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

As mobile technologies advance, healthcare is increasingly utilising mobile interventions to accompany traditional interventions such as psychotherapy. Mobile assessments of symptoms and other processes are also used as low-level interventions and are believed to lead to symptom improvements in patients with symptoms of depression, for example. However, robust evidence on the health benefits of monitoring interventions in patients with depression is lacking.

The investigators are interested in the potential benefits of a monitoring intervention as an add-on to face-to-face Cognitive Behavioral Therapy (CBT) for depression. Therefore, the investigators will conduct a randomised trial to investigate the effects of a monitoring intervention consisting of Ecological Momentary Assessment (EMA) of symptoms and inter-session processes via mobile phones. Twenty sessions of face-to-face CBT + EMA will be compared to twenty sessions of face-to-face CBT (treatment as usual, TAU). Participants in the CBT + EMA group will be asked to answer monitoring questions twice daily for two four-week blocks during the CBT treatment. A total of 84 participants with mild to moderate depression will be randomized. Of these, 48 participants will be randomized to CBT + EMA and 36 participants will be randomized to TAU. The primary outcome of interest is change in the Patient Health Questionnaire (PHQ-9) score at four-month follow-up assessment.

Throughout the study, there will be five assessment timepoints: Baseline (before the first therapy session), four weeks after the fourth therapy session, four weeks after the twelfth therapy session, after the last session (post-treatment) and the 4-month follow-up (four months after the last therapy session).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ICD-10 diagnosis of mild or moderate depression, first or recurrent episode (F32.0, F32.1, F33.0, F33.1)
  • PHQ-9 ≥ 5
  • Possession of smartphone with internet access
  • Signed informed consent

Exclusion criteria

  • Acute or past suicidality; self-reported
  • Acute addiction (F10 - F19)
  • Dysthymia (F34.1), postpartum depression, or severe depression (F32.3; F33.3)
  • PHQ-9 > 20
  • Depression not main mental health concern
  • Planned onset or planned change in antidepressant medication
  • History of psychotic symptoms, bipolar disorder, personality disorders, or organic brain disorders
  • Cognitive impairment or physical disability that would hinder psychotherapy or the use of a smartphone

Treatment and study plan

Cognitive Behavioural Therapy (CBT)

Behavioral

20 sessions of face-to-face, individual CBT

Ecological Momentary Assessment (EMA)

Other

Two four-week blocks of twice daily ecological momentary assessment (EMA) of symptoms and inter-session processes

Primary outcomes

  1. Patient Health Questionnaire (PHQ-9)

    Time frame: 4-month follow-up

    Participant-reported measure assessing depressive symptomatology. The total score of this nine-item scale ranges from 0-27, with higher scores indicating greater depression-symptom severity.

Secondary outcomes

  1. Patient Health Questionnaire (PHQ-9)

    Time frame: Baseline, 4 weeks after the 4th session, 4 weeks after the 12th session, immediately after the last session and the 4-month follow-up

    Participant-reported measure assessing depressive symptomatology. The total score of this nine-item scale ranges from 0-27, with higher scores indicating greater depression-symptom severity.

  2. Beck's Depression Inventory (BDI-II)

    Time frame: Baseline, 4 weeks after the 4th session, 4 weeks after the 12th session, immediately after the last session and the 4-month follow-up

    Participant-reported measure assessing changes in depressive symptoms. The total score of this twenty-one-item scale ranges from 0-63, with higher scores indicating greater depression severity.

  3. Certainty About Mental States Questionnaire (CAMSQ)

    Time frame: Baseline, 4 weeks after the 4th session, 4 weeks after the 12th session, immediately after the last session and the 4-month follow-up

    Participant-reported measure assessing mentalisation of oneself and others. The total score of this forty-item scale ranges from 40-280, with higher scores indicating a greater frequency of successful mentalisation.

  4. Dysfunctional Attitude Scale (DAS-18A)

    Time frame: Baseline, 4 weeks after the 4th session, 4 weeks after the 12th session, immediately after the last session and the 4-month follow-up

    Participant-reported measure assessing dysfunctional attitudes. The total score of this eighteen-item scale ranges from 18-126, with higher scores indicating greater levels of dysfunctional attitudes.

  5. Depression-Specific Self-Efficacy Expectation Questionnaire (DSWE)

    Time frame: Baseline, 4 weeks after the 4th session, 4 weeks after the 12th session, immediately after the last session and the 4-month follow-up

    Participant-reported measure assessing depression-specific self-efficacy. The total score of this five-item scale ranges from 0-25, with higher scores indicating greater levels of depression-specific self-efficacy.

  6. Evaluation of Treatment Progress Questionnaire (FEP-2)

    Time frame: Baseline, 4 weeks after the 4th session, 4 weeks after the 12th session, immediately after the last session and the 4-month follow-up

    Participant-reported measure assessing subjective treatment progress. The total score of this forty-item scale ranges from 40-200, with higher scores indicating poorer treatment outcome.

  7. Level of Personality Functioning Scale - Brief Form (LPFS-BF 2.0)

    Time frame: Baseline, 4 weeks after the 4th session, 4 weeks after the 12th session, immediately after the last session and the 4-month follow-up

    Participant-reported measure assessing the level of personality functioning. The total score of this twelve-item scale ranges from 12-48, with higher scores indicating lower levels of functioning.

  8. Positive and Negative Affect Schedule (PANAS)

    Time frame: Baseline, 4 weeks after the 4th session, 4 weeks after the 12th session, immediately after the last session and the 4-month follow-up

    Participant-reported measure assessing positive and negative affect using two subscales. The total score of each 10-item-subscale ranges from 10-50 with higher scores indicating greater levels of positive or negative affect in the corresponding subscales.

  9. Personality Inventory for DSM-5 - Brief Form Plus (PID-5-BF+ M)

    Time frame: Baseline, 4 weeks after the 4th session, 4 weeks after the 12th session, immediately after the last session and the 4-month follow-up

    Participant-reported measure assessing personality traits. The total score of this thirty-six-item scale ranges from 0-108, with higher scores indicating greater personality pathology.

  10. Health Survey - Short Form (SF-8)

    Time frame: Baseline, 4 weeks after the 4th session, 4 weeks after the 12th session, immediately after the last session and the 4-month follow-up

    Participant-reported measure assessing changes in health-related quality of life.The total score of this eight-item scale ranges from 8-42, with higher scores indicating poorer health-related quality of life.

  11. Symptoms Checklist (SCL-K-9)

    Time frame: Baseline, 4 weeks after the 4th session, 4 weeks after the 12th session, immediately after the last session and the 4-month follow-up

    Participant-reported measure assessing symptoms during psychotherapy. The total score of this nine-item scale ranges from 0-36, with higher scores indicating greater symptom severity.

  12. Treatment Satisfaction Questionnaire (ZUF-8)

    Time frame: Immediately after the last session

    Participant-reported measure assessing patients' satisfaction with treatment. The total score of this eight-item scale ranges from 8-32, with higher scores indicating greater treatment satisfaction.

Study contacts

Contact information is provided by the study sponsor or research team.

Fiona Fäh

CONTACT

[email protected]

+41 44 635 73 21

Louisa Jagmetti, M.Sc.

CONTACT

[email protected]

+41 44 635 73 28

Sponsors and collaborators

Lead sponsor

Birgit Watzke

Other

Collaborators

  • Universität Tübingen

Registry information

Acronym: ISA-Bell

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Sep 23, 2022
Registry last updated
Jun 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.